BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study

Becton, Dickinson and Company156 enrolled

Overview

This post-market study is being conducted to generate safety and performance data on the BD Prevue(TM) II Peripheral Vascular Access System with Cue(TM) Needle Tracking Technology. The data will be utilized to support regional registrations (for example, EU MDR), and document any unforeseen residual risks.

This is an observational post-market, human subject study to evaluate the safety and performance of the BD Prevue(TM) II Peripheral Vascular Access System with Cue(TM) Needle Tracking Technology. Subjects will be recruited for participation based on need for IV catheter (midline catheters included) placement in a hospital setting. Enrolled subjects will go through ultrasound-guided peripheral intravenous catheter (USGPIV) placement as part of their clinical care. USGPIV is defined as a procedure in which an ultrasound machine is used to assist a qualified health care provider with IV cannulation from skin puncture through venipuncture via direct visualization on the ultrasound machine in real time.

Study Type

OBSERVATIONAL

Enrollment

156

Conditions

BD Prevue II for Peripheral Intravenous Catheter Placement

Interventions

BD Prevue(TM) IIDEVICE

Ultrasound-guided peripheral intravenous catheter placement procedure using the BD Prevue(TM) II

Eligibility

Sex: ALLMin age: 1 Year

Medical Language ↔ Plain English

Inclusion Criteria: * Age 1 years, or older * A patient who is a candidate for an ultrasound-guided peripheral intravenous catheter (midline catheters included) placement procedure using BD PrevueTM II Peripheral Vascular Access System with CueTM Needle Tracking Technology as assessed per their clinician(s) * Able and willing to provide informed consent or legal authorized representative (LAR) authorized to give consent on behalf of the subject Exclusion Criteria: * Any patient in whom ultrasound procedure might interfere with medical care or create undue hardship * Known, or suspected, allergy to materials contained in the BD PrevueTM II Peripheral Vascular Access System with CueTM Needle Tracking Technology or accessories that may come in contact with the patient * Localized skin, tissue, or other clinical factors that would prevent completion of the ultrasound procedure * Previous medical history that would prevent completion of the ultrasound procedure

Locations (2)

Brookdale University Hospital & Medical Center

Brooklyn, New York, United States

Allegheny Health Network Research Institute

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

Primary Performance: To provide visualization of the target vessel in which to insert the chosen vascular access device

The PrevueTM II system is able to visualize the target vasculature (\>=70% with a 95% confidence interval)

Time frame: During the procedure

Primary Performance: To have successful vascular access either by cannulation or blood return.

Successful access with the vascular access device, either by cannulation or blood return (\>=70% with a 95% confidence interval)

Time frame: During the procedure

Primary Performance: To determine if BD Prevue(TM) II Peripheral Vascular Access System with Cue(TM) Needle Tracking Technology is able to provide visual needle tip location tracking to assist with insertion of the chosen vascular access device.

CueTM Needle Tracking System is able to properly display the location of the needle tip during vascular access device access insertion (\>=80% with a 95% confidence interval)

Time frame: During the procedure

Primary Safety: To determine the incidence of device related adverse events, experienced by patient or user, when using the BD PrevueTM II Peripheral Vascular Access System with CueTM Needle Tracking Technology

Rate of device related adverse events (\<2%).

Time frame: During the procedure and 15 minutes after the procedure

Secondary Outcomes

Secondary Performance: To have successful first-attempt vascular access either by cannulation or blood return when using the BD PowerGlide Pro midline catheter.

Successful first-attempt access with the PowerGlide Pro midline catheter, either by cannulation or blood return (\>=70% with a 95% confidence interval)

Time frame: During the procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.